Is hypocalcemia during therapy with zoledronic acid or other bisphosphonates beneficial to cancer patients?
Tanvetyanon
Tawee
T
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D002118:Calcium / Q000378:metabolism*; D004164:Diphosphonates / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D006996:Hypocalcemia / Q000139:chemically induced* / Q000378:metabolism*; D007093:Imidazoles / Q000008:administration & dosage* / Q000009:adverse effects; D008954:Models, Biological; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism*; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D016896:Treatment Outcome; D000077211:Zoledronic Acid
D020533:Angiogenesis Inhibitors; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid; D002118:Calcium